Product logins

Find logins to all Clarivate products below.


Breast cancer is the most prevalent malignancy in women in China. Chemotherapy was the mainstay of treatment, but China now has access to several cutting-edge premium-priced targeted therapies (e.g., pertuzumab [Roche’s Perjeta], ado-trastuzumab emtansine [Roche’s Kadcyla]). The inclusion of these therapies in the National Reimbursement Drug List (NRDL) has improved drug-treatment rates for breast cancer in China and led to significant market growth. During the forecast period, we anticipate that newer treatment options will be introduced there, fueling further market expansion. In this report, we assess how clinical and nonclinical factors—price dynamics, inclusion in the NRDL—will influence the launch and uptake of new therapies for breast cancer during the forecast period. Understanding the impact of these intersecting factors will be key to the success of current and future players in this burgeoning pharmaceutical market.

QUESTIONS ANSWERED

  • What is the diagnosed incidence of breast cancer in China, and how are patients there treated? Do treatment management strategies differ between urban and rural China?
  • What are interviewed experts’ insights into current treatment options?
  • What are the key unmet needs in the management of breast cancer in China?
  • What are the key market access considerations, and how are they likely to impact the uptake of emerging breast cancer therapies in China?
  • What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?

PRODUCT DESCRIPTION

China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

July 2023

Geography

China

Primary research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists

Epidemiology

Diagnosed incidence of breast cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations

FORECAST

10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions

EMERGING THERAPIES

Phase III/preregistered: 20+ drugs; Phase II: 20+ drugs; coverage of select Phase I products

Related Market Assessment Reports

Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Heart Failure – Geographic Focus: China – China In-Depth – Heart Failure
Heart failure remains a significant public health challenge in China, driven by urbanization, an aging population, and sedentary lifestyles. The treatment of acute heart failure (AHF) still largely…